Fidelity Investments’s TransCode Therapeutics RNAZ Stock Holding History

Fidelity Investments’s Portfolio RNAZ Stock Details RNAZ Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-3	Closed	-$23	–	5553
2025 Q2	$23	Buy	3 +2	+200%	+$19	﹤0.01%	5260
2025 Q1	$12	Buy	+1	New	+$128	﹤0.01%	5243
2024 Q4	–	Hold	0	–	-$100	–	5774
2024 Q3	–	Hold	0	–	–	–	5096

Other funds holding RNAZ

DRW Securities Chicago, Illinois $7.21B AUM 20.54% 1-Year Est. Return

Citigroup New York $303B AUM 53.02% 1-Year Est. Return

FDCDDQ

Federation des caisses Desjardins du Quebec Levis, Quebec, Canada $27.8B AUM 31.66% 1-Year Est. Return

TRCT

Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return

SBI Securities Tokyo, Japan $4.4B AUM 74.26% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return

Fidelity Investments's RNAZ Position: Q3 2025 in Review

Fidelity Investments sold out of TransCode Therapeutics (RNAZ) in Q3 2025, closing a stake of 3 shares — an estimated $23 sold.

Fidelity Investments first reported a position in RNAZ in Q1 2025 and held it in 2 quarters. The position peaked at $23 in Q2 2025. 8 funds tracked by Wall St. Rank hold RNAZ as of Q3 2025.

Fidelity Investments reported no remaining TransCode Therapeutics position as of Q3 2025 after selling out during the quarter.
Fidelity Investments sold 3 TransCode Therapeutics shares in Q3 2025, an estimated $23.
Fidelity Investments first reported a position in TransCode Therapeutics in Q1 2025 and held it in 2 quarters.
Fidelity Investments's TransCode Therapeutics position peaked at $23 in Q2 2025.
8 funds tracked by Wall St. Rank held TransCode Therapeutics as of Q3 2025.

Based on Fidelity Investments's 13F filing for Q3 2025, filed 13 Nov 2025.